KALVISTA PHARMACEUTICALS INC (KALV)

Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.

Curious about the stocks that are showing activity before the opening bell on Tuesday?

Oversold Conditions For KalVista Pharmaceuticals (KALV)

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

Investors Land KALV Even Lower Than Its Secondary Stock Offering

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

Oversold Conditions For KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

KalVista Appoints Brian Piekos as Chief Financial Officer

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

Notable Friday Option Activity: CVNA, KALV, ACI

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium

Notable Monday Option Activity: FUBO, RKLB, KALV

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024

KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the fourth quarter of 2024.

KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips KalVista Pharma (NASDAQ:KALV) just reported results for the fourth quarter of 2...

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

KALV Makes Notable Cross Below Critical Moving Average

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema